CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a pacesetter within the subject of mobile metabolism pioneering therapies for uncommon and genetically outlined ailments, in the present day introduced the grant of inducement fairness awards outdoors of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones. The grants had been authorized by the Board of Directors efficient as of September 26, 2022 as inducements materials to Ms. Jones coming into into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consisted of (i) a nonstatutory choice to buy as much as 118,390 shares of widespread inventory, (ii) restricted inventory items for 22,417 shares of widespread inventory and (iii) efficiency inventory items for 10,760 shares of widespread inventory. The possibility has an train worth of $27.88 per share, the closing worth per share of the Company’s widespread inventory as reported by Nasdaq on September 26, 2022. The possibility has a ten-year time period and vests over 4 years, with 25% of the unique variety of shares vesting on the primary anniversary of Ms. Jones’ begin date and a pair of.0833% of the shares underlying the choices vesting month-to-month thereafter, topic to her continued service with the Company via the relevant vesting dates. Each restricted inventory unit will entitle Ms. Jones to obtain one share of the Company’s widespread inventory for every restricted inventory unit that vests. The restricted inventory items will vest in equal annual installments on every anniversary of Ms. Jones’ begin date, till the third anniversary of such date, topic to her continued service with the Company via the relevant vesting dates. Each efficiency inventory unit represents a contingent proper to obtain one share of the Company’s widespread inventory upon the achievement of specified efficiency milestones.
About Agios
Agios is a biopharmaceutical firm that’s fueled by connections. The Agios crew cultivates sturdy bonds with affected person communities, healthcare professionals, companions and colleagues to find, develop and ship therapies for uncommon and genetically outlined ailments. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the primary disease-modifying remedy for this uncommon, lifelong, debilitating hemolytic anemia. Building on the corporate’s management within the subject of mobile metabolism, Agios is advancing a sturdy medical pipeline of investigational medicines with energetic and deliberate packages in alpha- and beta-thalassemia, sickle cell illness, pediatric PK deficiency and MDS-associated anemia. In addition to its medical pipeline, Agios has a number of investigational therapies in preclinical growth and an industry-leading analysis crew with unmatched experience in mobile metabolism and genetics. For extra info, please go to the corporate’s web site at www.agios.com.
Contact
Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
[email protected]
Media:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
[email protected]
